Scholarlink

Background <p>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) including umbilical cord blood transplantation (UCBT) is considered to be a potentially curative treatment for acute myeloid leukemia (AML). However, post-transplantation complications continue to be a leading cause of morbidity and mortality in transplant recipients, presenting significant ongoing challenges in the field. Herein, we reported a rare case who successfully recovered from concurrent nephrotic syndrome (NS) and Guillain-Barré syndrome (GBS) following UCBT in AML.</p> Case presentation <p>A 66-year-old female was diagnosed with high-risk AML, who achieved complete remission with venetoclax and azacitidine treatment, followed by double-unit UCBT. Five days pre-transplant, COVID-19 was diagnosed and resolved prior to engraftment. Post-transplant complications included acute cutaneous graft-versus-host disease (day + 22), NS (day + 82), and GBS (day + 106), temporally associated with COVID-19. The patient was diagnosed with NS based on clinical and laboratory criteria as renal biopsy was deferred due to frailty. Treatment involved prednisone, continuous renal replacement therapy, intravenous immunoglobulin and double-filtration plasmapheresis. Despite superimposed infections, the patient achieved complete resolution of proteinuria, neurological recovery, and glucocorticoid discontinuation through multidisciplinary intervention.</p> Conclusion <p>NS and GBS are rare immune-mediated complications post-UCBT, potentially induced by SARS-CoV-2-mediated immune dysregulation in this case. Successful outcomes depend on early recognition, active interventions, and coordinated critical care support.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nephrotic syndrome and Guillain-Barré syndrome following umbilical cord blood transplantation in acute myeloid leukemia: correlated with COVID-19?

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月29日

查看全文
  • Jing-dong Zhou,
  • Ming-qiang Chu,
  • Yuan Feng,
  • Yong-hui Ji,
  • Xiao-peng Chen,
  • Ting-juan Zhang,
  • Jun Qian

摘要

Background

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) including umbilical cord blood transplantation (UCBT) is considered to be a potentially curative treatment for acute myeloid leukemia (AML). However, post-transplantation complications continue to be a leading cause of morbidity and mortality in transplant recipients, presenting significant ongoing challenges in the field. Herein, we reported a rare case who successfully recovered from concurrent nephrotic syndrome (NS) and Guillain-Barré syndrome (GBS) following UCBT in AML.

Case presentation

A 66-year-old female was diagnosed with high-risk AML, who achieved complete remission with venetoclax and azacitidine treatment, followed by double-unit UCBT. Five days pre-transplant, COVID-19 was diagnosed and resolved prior to engraftment. Post-transplant complications included acute cutaneous graft-versus-host disease (day + 22), NS (day + 82), and GBS (day + 106), temporally associated with COVID-19. The patient was diagnosed with NS based on clinical and laboratory criteria as renal biopsy was deferred due to frailty. Treatment involved prednisone, continuous renal replacement therapy, intravenous immunoglobulin and double-filtration plasmapheresis. Despite superimposed infections, the patient achieved complete resolution of proteinuria, neurological recovery, and glucocorticoid discontinuation through multidisciplinary intervention.

Conclusion

NS and GBS are rare immune-mediated complications post-UCBT, potentially induced by SARS-CoV-2-mediated immune dysregulation in this case. Successful outcomes depend on early recognition, active interventions, and coordinated critical care support.